Skip to main content
Caplight Logo









SynRx Therapeutics

SynRx Therapeutics

Private
HangzhouHealthcare & Life Scienceshttps://www.synrx.cn/

Last Round

Series A

Dec 8, 2025

Total Funding Raised

$28.3M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

SynRx Therapeutics is a biotechnology company that develops innovative oncology therapeutics focused on DNA damage repair pathways.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

precision oncologysynthetic lethalityDNA damage repairDDRPolθ inhibitorsmall molecule drugdrug discoverybiotech startuphomologous recombination repairsolid tumor therapyPARP inhibitor resistanceclinical developmentdrug licensingcancer researchpharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SynRx Therapeutics Comparables

Compare SynRx Therapeutics with similar companies based on industry and business-model similarity.

SynRx Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MOMA Therapeutics
88%
Breakpoint Therapeutics
86%
Recombination Therapeutics
86%

SynRx Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 8, 2025
Pre SeedNov 16, 2022

SynRx Therapeutics Investors

Notable investors and investment history

SynRx Therapeutics investors
InvestorRounds
Lapam CapitalSeries A, Pre Seed
杭州市人才集团有限公司Series A
Zhejiang Financial HoldingSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 8, 2025

    $14.1M round led by Zhejiang Financial Holding.

  • Nov 16, 2022

    $14.2M round led by Lapam Capital.

SynRx Therapeutics Filings

Explore SEC and related filing metadata, where available.

SynRx Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about SynRx Therapeutics's valuation, stock price, and market status.

Is SynRx Therapeutics a public or private company?

SynRx Therapeutics is a private company.

What is the current stock price of SynRx Therapeutics?

SynRx Therapeutics is a private company with no public stock price. Caplight tracks SynRx Therapeutics's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is SynRx Therapeutics worth (valuation)?

Valuation information for SynRx Therapeutics is not publicly available.

Can I buy SynRx Therapeutics stock?

SynRx Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was SynRx Therapeutics's last funding round?

SynRx Therapeutics's most recent funding round was Series A on December 8, 2025.

Who are the main investors in SynRx Therapeutics?

Key investors in SynRx Therapeutics include Zhejiang Financial Holding.

Will SynRx Therapeutics IPO soon?

No public IPO plans have been announced for SynRx Therapeutics.

How can I track SynRx Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SynRx Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHangzhou
Year Founded2021
Last FundingDec 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?